BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

About Image

BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin (BoNT).

Mapp and its collaborators will isolate, screen, and characterize BoNT monoclonal antibodies, ultimately combining them into a “pan-BoNT" therapeutic treatment made up of four or fewer mAbs. The treatment would address all seven major types of Botulinum. The top antibody candidates will be expressed in a Chinese Hamster Ovary (CHO) cell expression system which eliminates the need to collect antibodies from human and other animal sources.

Currently, two effective medical countermeasures are available to treat Botulinum neurotoxins; however, both of the MCMs rely on a dwindling supply of polyclonal immunoglobulin from human or equine sources, and only one, HBAT, addresses all seven serotypes of Botulinum. New therapeutic interventions are a critical public health need.

About Mapp Biopharmaceutical, Inc.:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

Last Updated: October 05, 2020